Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

I assume you are worried about growth after 2028.

There are no growth concerns between now and 2028 EVEN IF HALO HAS ZERO NEW PARTNERS OR ZERO NEW INNOVATIONS. The existing programs with no new deals are giving us 20-30% growth in EPS through 2027. (See Halo’s Jan financial update, slide 27 regarding 5 year EBITA and EPS growth based purely on existing programs)

Yes we need new partners and innovation after that to keep the existing rapid growth going past 2028. Yes, Helen dropped the ball on this for the past 14 months. But there have been plenty of successes with new deals prior to 2023 and there is good chance we will see more with or without the current CEO.

The stock got punished more than it deserved for lack of execution in just a single year. There was plenty of success in other years and that’s why we have amazing fundamentals now and for the next five years.

A similar negative sentiment was shared by a couple of posters on this board (including you) when PEGPH2 failed. Folks were so focused on that one failure that they missed all the other successes. This is why a few here didn’t like halozyme when it was trading in single digits and teens just a few years ago. I loaded up and posted numerous time here on this board back then. I think it is undervalued now as it was then despite the recent management failure.